​Our Medical Devices business unit covers all appointments across Business Development, Account Management, Engineering and Project Management, with a global footprint expanding Europe and USA.

​

Over the past six months, the Medical Devices industry has been extremely busy with open positions within Microscopy, Fluorescent Imaging, 3D Bioprinting, Medication Delivery and Vaccines. Below are a few key moves that have taken place within this space…

Rom Mendel, Chairman of the Board

Moved to: Duearity AB

Moved from: Cochlear

Sector: Medical Devices

Rom is an experienced and inspiring Executive Leader with over 20 years’ experience and a proven track record driving growth in international Life Science and Technology companies, having worked in several countries including the US, Japan, Denmark and Sweden. As well as founding Clear Path Management AB earlier this year, he also joined Duearity AB as Chairman of the Board. Before making this move, Rom was Managing Director at Cochlear for 14 years. Rom's approach to leadership revolves around a culture of collaboration and genuine care for employees development and wellbeing.

​

Anne Jones, Chief Business Officer

Moved to: Celularity, Inc.

Moved from: Genuity Science

Sector: Biotechnology

Anne is an Executive Leader with over 25 years' experience leading teams and businesses in world class public corporations, as well as within the private sector in the Life Sciences, Healthcare and Diagnostics arenas. Before making the move over to Celularity as CBO, Anne held key leadership positions including COO at Genuity Science, CEO at Genomics Medicine Ireland, and VP at Pall Corporation. She specialises in creating off-the-shelf cellular medicines and has led large and diverse teams up to 800 people, all of which will aid her in her role as CBO at Celularity.

​

Jack Egelund, Chief Executive Officer

Moved to: Diagonal Bio

Moved from: Clinical Microbiomics

Sector: Biotechnology

Jack was appointed as CEO at DiagonalBio earlier this year, making the move over from Clinical Microbiomics where he served as Chief Business Officer. Jack has a PhD in Biotechnology from the University of Copenhagen and studied Business Administration at Copenhagen Business School, along with a wide range of experience from management positions within the Life Sciences industry. His unique background spans both the commercial as well as the scientific. Jack's ethos as a leader involves setting direction for his team, motivating and presenting content to ensure support, an creating clear visions of the future.

​

Alessandre Keller, Chief Executive Officer

Moved to: Unilabs

Moved from: Nestlé

Sector: Biotechnology

Alessandre is an experienced global business leader, with a demonstrated track record in the healthcare, nutrition, and food & beverages industry. At the turn of this year, Alessandre joined Unilabs Switzerland, the leading European diagnostic services provider, as CEO. He made the move over to Unilabs from Nestlé, the world's largest food company, where he served as Vice President and Global Business Head. Alessandre's sharp business acumen, international experience and operational expertise is sure to be a huge asset as Unilabs Switzerland continues to go from strength to strength.

​

Atul Dandekar, Chief Strategy Officer

Moved to: Maze Therapeutics

Moved from: Genentech

Sector: Biotechnology

To keep up with their growth, earlier this year Maze Therapeutics appointed pharma business leader Atul as Chief Strategy Officer. Atul brings with him over 25 years' experience in strategy, clinical development and commercialisation for biotech and pharmaceutical companies. Prior to joining the leadership team at Maze Therapeutics, he served as Vice President, Global Franchise Head for Ophthamology at Genetech. In his role at Maze Therapeutics, he will lead corporate strategy development, product & disease area strategy, and portfolio management, and will help advance the precision therapies to clinical development.

​

A NOTE FROM OUR CEO: Alessandro Mantell

It is with great pride and excitement that Mantell Associates have launched our first ever ‘Movers & Shakers’, which has been designed to highlight some of the biggest moves across the Life Science & Pharmaceutical Industry within the first six months of 2021.

Anyone who has followed the Mantell Associates journey so far will see the great extent of the effort and care that we have invested into making Mantell Associates not just ‘another recruitment business’ but a truly specialist, high-level headhunting organisation. We focus on Senior level appointments and consulting services, but we strive to share market intelligence and industry relevant content, and to provide exposure for individuals and businesses through the Mantell Associates Network podcast, which has already featured 21 industry leaders. In this ‘Movers & Shakers’ we look at the high level leadership moves between January and June this year, in particular across CDMO Large Molecule, CDMO Small Molecule, Life Sciences, Medical Devices & Consultancies, Market Access, HEOR. The incredible people and businesses that we highlight in this particular ‘Movers & Shakers’ are not only those who changed role but rather those who, during an incredibly difficult time, saw an opportunity to make an impact on the world and those around them.

Thank you from all of the Mantell Associates team – we hope you enjoy it!